Perfil epidemiológico e farmacológico de pacientes hematológicos internados em um hospital escola no interior do estado do Rio Grande do Sul

Abstract

Hematologic diseases are a type of neoplasm that are part of a diverse group of diseases affecting pluripotent cells. By obtaining information from epidemiological data on hematologic diseases, it is possible to understand the incidence and prevalence by quantifying different populations and identifying groups at higher risk. The aim of this study was to demonstrate, through epidemiological and pharmacological profiles, the main characteristics of patients with hematologic diseases treated at a teaching hospital in the interior of Rio Grande do Sul state. The methodology involved reviewing medical records and literature review. This was an observational and retrospective study, approved by the ethics committee of the Federal University of Santa Maria under number: 64468622.6.0000.5346. Among the 25 patients included in the study, Non-Hodgkin Lymphoma had the highest prevalence (20%), followed by Multiple Myeloma and Acute Myeloid Leukemia, each with 12%. Hodgkin Lymphoma, Myeloproliferative Neoplasms, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, and Chronic Myeloid Leukemia each had an incidence of 8%. Myelodysplastic Syndrome, Peripheral T-cell Lymphoma, Hairy Cell Leukemia, Aplastic Anemia, and Idiopathic Thrombocytopenic Purpura had an incidence of 4%. Of the participants, 48% were men and 52% were woman, with the majority being over 60 years old (44%), followed by 41 to 60 years old (32%), 21 to 40 years old (20%), and under 20 years old (4%). All participants were using more than five drugs, considering only medications listed in the hospitalization medical prescription, and 44% were undergoing chemotherapy. It is expected that the data provided in this study on the epidemiological and pharmacological profiles of patients with hematologic diseases at this teaching hospital will assist in the management of this and other hospitals in the treatment and recovery of complications related to hematologic diseases.